The South San Francisco, CA-based biopharmaceutical firm leverages its oligonucleotide and small molecule platforms to develop medication to be used in combo regimens for viral and liver illnesses. Lead program, comprised of 4 candidates, is geared toward a useful remedy for power hepatitis B virus (HBV) an infection. One other program, with one candidate at current, is concentrated on NASH, presently preclinical.
2020 Financials (6 mo.): Working Bills: $42.0M (+99%); Internet Loss: ($40.8M) (-104%); Money Burn: ($38.0M) (-108%).